ExpertiseUpdated on 9 September 2024
Viral vector development for gene delivery/gene therapy
About
Sagitta's viral vector have a large payload capacity (up to 18kbp), and can express affinity proteins in order to infect only cells carrying specific markets (tumor marker, cell type, etc).
In addition, Measles surface proteins have been removed, to avoid pre-existing MV immunity. The vector do not elicit any neutralizing immune response.
Our technology has the capacity to offer several benefits over Adeno/AAV technologies, and we are looking for partners to explore this opportunity.
Similar opportunities
Service
Global Cell and Gene Therapy CDMO
- Development
- Manufacturing
Matthew Cobb
Senior Account Director at Catalent Cell and Gene Therapy
Cambridge UK, United Kingdom
Service
Strategy Development: From Idea to Market
- Consulting
- Biotech and Lifescience
Paul Riley
Pharma & Life Sciences Consultant at Nexcea
Manchester, United Kingdom
Service
Chromatography & Mass Spectrometry Instrument Service/Maintenance
- Others
- Biotech and Lifescience
Adel Abrar
Business Development Specialist at Jaytee Biosciences
Macclesfield, United Kingdom